Direct thrombin inhibitor offers the advantage of not needing prothrombin time controls and dose adjustments, but it needs large clinical trial for confirmation.

• 新一世代抗凝血剂似乎具有较高的安全性及使用之方便性，但是仍待大规模的临床试验来证实。